Skip to content

Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission

Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02990520
Acronym
MASS
Enrollment
190
Registered
2016-12-13
Start date
2015-02-28
Completion date
2024-02-02
Last updated
2024-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition, Sarcopenia

Brief summary

The purpose of this study is to determine the prevalence of malnutrition and/or sarcopenia at admission to the hospital in older adults.

Detailed description

The primary outcome of this study is to determine the prevalence of malnutrition and/or sarcopenia at admission to the hospital in older adults. The secondary outcome is to assess the relationship between malnutrition/sarcopenia status and length of stay, comorbidity load, polypharmacy, and 30-day readmission.

Interventions

None listed

Sponsors

The University of Texas Medical Branch, Galveston
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to the UTMB ACE unit * Aged 65 years or older * Able to consent to participate in study (alert and oriented x3)

Exclusion criteria

* Because this study aims to determine prevalence of malnutrition and/or sarcopenia at admission to the hospital, patients will be excluded if study measures are not able to be taken within 72 hours of admission.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Malnutritionbaselinemalnutrition measured with questionnaires

Secondary

MeasureTime frameDescription
Prevalence of sarcopeniabaselineSarcopenia defined using the EWGSOP or IWGS or FNIH criteria

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026